Based on flow cytometric assessment of CD19 expression in B-ALL, relapse after CD19 CAR-T cell treatment can be divided into two groups: CD19-negative relapse and CD19-positive relapse (28, 29). The gene discussed is CD19; the disease is acute lymphoblastic leukemia.